The National Institutes of Health has begun an early stage study on its experimental vaccine targeting six strains of influenza virus.

Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, independent of symptom changes, new research suggested.

Dana-Farber Cancer Institute is investigating allegations of data manipulation in dozens of research papers, some of which were authored by high-profile investigators.

In a proposed guidance, the FDA voiced concerns over whether cancer clinical trials largely or entirely conducted outside the United States are relevant to US patients.

Promising preclinical and early clinical data suggest a role for GLP-1 receptor agonist therapy in treating alcohol use disorder.

Famed microbiome researcher Dr Martin J. Blaser shares what he sees as the most promising applications, and the rigorous clinical trials needed to realize them.

Patients with transthyretin amyloid cardiomyopathy taking tafamidis have less worsening of cardiac function than those on placebo, post hoc analysis of randomized results suggests.

Alopecia, dysesthesia, and other types of skin sensations have been reported in patients treated with semaglutide, but more research is needed to understand skin findings associated with this drug.

The Heart Failure Society of America (HFSA) has cancelled its annual scientific meeting, scheduled to begin today in Atlanta, Georgia, due to Hurricane Helene.

Over half of patients with symptoms of gastroparesis have low vitamin D levels, which is linked to heightened nausea, vomiting, and gastric neuromuscular dysfunction.

MS that develops after age 50 tends to progress more rapidly than younger-onset MS and is less apt to respond to disease-modifying therapy, Swedish registry data show.

The HIPPOCRATES consortium aims to help predict those who will develop the condition, diagnose it earlier, and one day even prevent it.

Phase 2b study data also showed a dose reduction in glucocorticoids among those who received the investigational drug compared with patients who received placebo.

Only a minority of genome-targeted cancer drugs recently approved in the United States demonstrate significant clinical benefits to patients, a new analysis found.

Media reports touting ketamine as a miracle drug for severe depression have contributed to confusion about the differences between ketamine and its esketamine, experts said.

Transcranial alternating current stimulation reduces insomnia severity, increases total sleep time, and alleviates daily disturbances such as fatigue.

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.

The FDA recently declined to approve MDMA-assisted therapy for PTSD, but experts said there are many other treatments on the horizon.

The American Medical Association and specialty medical organizations encourage vaccinations and offer resources for clinicians.

The U.S. Food and Drug Administration approved IntraBio's drug for a rare and fatal genetic disorder, the health regulator said on Tuesday, just days after the agency...